APRE
Aprea Therapeutics, Inc.
Healthcare — Biotechnology
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
None
4 analysts
$0.72
$-0.03 (-4.00%)
Target:
$4.30
(497.2%)
Price History
Sign in to add APRE to a watchlist or set price alerts.
Fundamentals
| Market Cap | $8.91M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.91 |
| EPS (TTM) | $-1.49 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $4.30 |
| Analysts | 4 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 55.9 |
| Beta | 1.56 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | - |
Performance Analysis
BULLISHAPRE shows predominantly bullish signals based on its fundamentals and technicals.
+
RSI at 55.9 shows positive momentum.
~
Wall Street consensus is "none" from 4 analysts.
+
Average analyst target of $4.30 implies 497.2% upside.
Recent News
Loading news...
Last updated: Jul 01, 2026 15:01 UTC
Back to Screener Export Report